Quinolone resistance and Campylobacter spp

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Campylobacter species are a common cause of human diarrhea.
• Fluoroquinolones were initially considered effective for treating campylobacter infections.
• Emerging fluoroquinolone resistance in Campylobacter poses a significant public health challenge.

Purpose of the Study:

• To investigate the prevalence and mechanisms of fluoroquinolone resistance in Campylobacter isolates.
• To explore factors contributing to the rise of resistant strains, including veterinary use.
• To assess the clinical implications of fluoroquinolone resistance in campylobacter infections.

Main Methods:

• Analysis of in-vitro susceptibility data for Campylobacter species against fluoroquinolones.
• Review of clinical trial outcomes for fluoroquinolone treatment of campylobacter enteritis.
• Genetic analysis of fluoroquinolone-resistant isolates, focusing on gyrA gene mutations.
• Examination of epidemiological data correlating resistance with fluoroquinolone usage in human and animal populations.

Main Results:

• Up to 50% of human Campylobacter isolates exhibit fluoroquinolone resistance.
• Resistance is frequently associated with mutations in the gyrA gene (threonine 86).
• Fluoroquinolone resistance has been linked to treatment failures in patients with campylobacter infections.

Conclusions:

• Fluoroquinolone resistance is a significant issue in Campylobacter, impacting treatment efficacy.
• The widespread use of fluoroquinolones, potentially including veterinary applications, may drive resistance.
• Continued monitoring of resistance patterns and responsible antibiotic stewardship are crucial.